Morgan Stanley Athenex, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.12 - $0.21 $1,577 - $2,761	13,148 Added 10.08%	143,594 $21,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $1.11 $24,858 - $114,972	-103,579 Reduced 44.26%	130,446 $35,000
Q2 2022 Oct 27, 2022	BUY	$0.41 - $0.91 $25,197 - $55,926	61,458 Added 35.61%	234,025 $96,000
Q2 2022 Aug 15, 2022	BUY	$0.41 - $0.91 $25,197 - $55,926	61,458 Added 35.61%	234,025 $96,000
Q1 2022 Oct 27, 2022	SELL	$0.79 - $1.59 $48,551 - $97,718	-61,458 Reduced 26.26%	172,567 $142,000
Q1 2022 May 13, 2022	SELL	$0.79 - $1.59 $680,009 - $1.37 Million	-860,772 Reduced 83.3%	172,567 $142,000
Q4 2021 Feb 14, 2022	SELL	$1.36 - $2.94 $688,234 - $1.49 Million	-506,055 Reduced 32.87%	1,033,339 $1.41 Million
Q3 2021 Nov 15, 2021	BUY	$2.97 - $4.84 $4.57 Million - $7.45 Million	1,539,394 New	1,539,394 $4.63 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.